Prophylactic warfarin therapy after primary percutaneous coronary intervention for anterior st-segment elevation myocardial infarction

JACC: Cardiovascular Interventions

Volumn 8, Issue 1, 2015, Pages 155-162

  Le May, Michel R ^a   Acharya, Sudikshya ^a   Wells, George A ^a   Burwash, Ian ^a   Chong, Aun Yeong ^a   So, Derek Y ^a   Glover, Chris A ^a   Froeschl, Michael P V ^a   Hibbert, Benjamin ^a   Marquis, Jean Franc¸ois ^a   Dick, Alexander ^a   Blondeau, Melissa ^a   Bernick, Jordan ^a   Labinaz, Marino ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Angioplasty; Oral anticoagulation; Primary percutaneous intervention; ST segment elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEMOGLOBIN; HEPARIN; HIRULOG; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

AKINESIA; ANTICOAGULANT THERAPY; APICAL AKINESIS; APICAL DYSKINESIS; ARTICLE; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; DYSKINESIA; FOLLOW UP; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART REINFARCTION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSTHORACIC ECHOCARDIOGRAPHY; ADVERSE EFFECTS; AGED; ANTERIOR WALL MYOCARDIAL INFARCTION; BLEEDING; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG EFFECTS; DRUG THERAPY; FEMALE; HEART LEFT VENTRICLE FUNCTION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROPENSITY SCORE; RECURRENT DISEASE; RISK; RISK FACTOR; STATISTICAL MODEL; STROKE; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTERIOR WALL MYOCARDIAL INFARCTION; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; RECURRENCE; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; WARFARIN;

EID: 84921415537     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.07.018     Document Type: Article

References (28)

1. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998;98: 1597-603.
2. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71.
3. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334: 1084-9.
4. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998;98:2126-32.
5. DeEugenio D, Kolman L, DeCaro M, et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy 2007;27:691-6.
6. Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006;18:162-4.
7. Mattichak SJ, Reed PS, Gallagher MJ, Boura JA, O'Neill WW, Kahn JK. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol 2005;18: 163-6.
8. Rossini R, Musumeci G, Lettieri C, et al. Longterm outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008;102:1618-23.
9. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78-140.
10. Le May MR, So DY, Dionne R, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2008;358: 231-40.
11. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 2004;44: E1-211.
12. Van de WF, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909-45.
13. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
14. Mulvagh SL, Rakowski H, Vannan MA, et al. American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. J Am Soc Echocardiogr 2008;21:1179-201.
15. Burwash IG, Basmadjian A, Bewick D, et al. 2010 Canadian Cardiovascular Society/Canadian Society of Echocardiography Guidelines for Training and Maintenance of Competency in Adult Echocardiography. Can J Cardiol 2011;27: 862-4.
16. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9.
17. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
18. Nikolsky E, Mehran R, Dangas GD, et al. Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). Am J Cardiol 2012;109:831-8
19. Ruiz-Nodar JM, Marin F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fi brillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008;51:818-25.
20. Zhao HJ, Zheng ZT, Wang ZH, et al. "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 2011;139:260-70.
21. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12.
22. Porter A, Kandalker H, Iakobishvili Z, et al. Left ventricular mural thrombus after anterior ST-segment-elevation acute myocardial infarction in the era of aggressive reperfusion therapy-still a frequent complication. Coron Artery Dis 2005;16: 275-9.
23. Osherov AB, Borovik-Raz M, Aronson D, et al. Incidence of early left ventricular thrombus after acute anterior wall myocardial infarction in the primary coronary intervention era. Am Heart J 2009;157:1074-80.
24. Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 2009;53:2019-27.
25. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003;92:930-5.
26. Doyle BJ, Ting HH, Bell MR, et al. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. J Am Coll Cardiol Intv 2008;1: 202-9.
27. Chase AJ, Fretz EB, Warburton WP, et al. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R. T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart 2008;94: 1019-25.
28. Naruse Y, Sato A, Hoshi T, et al. Triple antithrombotic therapy is the independent predictor for the occurrence of major bleeding complications: analysis of percent time in therapeutic range. Circ Cardiovasc Interv 2013;6:444-51.